Health · NASDAQ · USD · Data as of 2026-07-30
AUM
$395.55M
Expense ratio
0.35%
Yield
0.47%
YTD return
+7.41%
Last price
$208.74
Thematic Sector · Coverage 100% · medium
Today
59.5
Outlook
53.5
Block A (composite-derived)
52.8
Block C (market behavior)
65.2
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
52.8
Coverage 100% · high
Liquidity
54.4
Expenses
80.0
Performance
32.9
Volatility
44.2
Dividend
12.4
Concentration
25.0
Smart Money
73.1
Activist
100.0
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
VanEck Biotech ETF (BBH) is an exchange-traded fund from VanEck in the Mixed asset class. Launched in 2011. Assets under management: 364,661,248.
Bullish Whales composite rating: 53 out of 100. Evidence coverage 100% across 8 of 8 axes. Strongest axes: activist exposure, expenses, smart-money flow.
Annualized one-year realized volatility 19%, classified moderate. Weakest axes: dividend, concentration.
Top-10 weight 1%, diversified, led by AMGN. Trailing yield 0%.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, dividend_score, expenses_score, smart_money_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yThe VanEck Biotech ETF is an exchange-traded fund that offers investors targeted exposure to the biotechnology sector, one of the most dynamic and research-intensive segments of the healthcare industry. This ETF primarily invests in a diversified portfolio of leading biotechnology companies, including firms involved in the development and commercialization of new drugs, therapies, and technologies. The fund seeks to replicate the performance of its underlying index, which is designed to track the overall trends in the biotech industry. The VanEck Biotech ETF plays a pivotal role in providing investors with opportunities to benefit from advancements in medical research, genetic engineering, and bioinformatics. By encompassing a wide array of companies at different stages of development, from emerging innovators to established leaders, the ETF serves as a barometer of technological advancements and regulatory developments within the biotech sector. Its strategic focus on biotechnology allows investors to participate in the potential growth of this high-impact industry while managing the assessment of risks associated with individual bioscience stocks.
30-day change
$28.69M
90-day change
—
Current AUM: $395,554,688. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BBH are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.